Equities researchers at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback